Discovery of novel candidate oncogenes in pancreatic carcinoma using high-throughput microarrays

Hepato-Gastroenterology

Volumn 60, Issue 128, 2013, Pages 1825-1832

  Jiang, Yajian ^a   Liu, Mingdong ^b   Li, Zhaoshen ^c   Jiang, Yegui ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CDH3 gene; Microarray; Pancreatic carcinoma; REG4 gene; S100P gene

Indexed keywords

ACTIN RELATED PROTEIN 2-3 COMPLEX; ACTIVAUNG TRANSCRIPTION FACTOR 6; CALCIUM BINDING PROTEIN; CASPASE 2; CASPASE 6; CATHEPSIN B; CYCLIN B1; CYCLIN G1; EPOXIDE HYDROLASE; EUKARYOTIC TRANSLATION INITIATION FACTOR 4 GAMMA 3; GLYCINE DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; P CADHERIN; PROTEIN TYROSINE PHOSPHATASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RGS2 PROTEIN; RIBOSOMAL PROTEIN L22; RIBOSOMAL PROTEIN L36; RIBOSOMAL PROTEIN S14; RIBOSOME PROTEIN; S100 CALCIUM BINDING PROTEIN G; SQUAMOUS CELL CARCINOMA ANTIGEN; STAT1 PROTEIN; TATA BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CALCIUM BINDING; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CHRONIC PANCREATITIS; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; ONCOGENE; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; UPREGULATION;

ADULT; AGED; BLOTTING, NORTHERN; CADHERINS; CALCIUM-BINDING PROTEINS; CARCINOMA; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LECTINS, C-TYPE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84893665135     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13343     Document Type: Article

References (62)

1. Jemal A, Siegel R, Ward E, et al.: Cancer Statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Chappuis PO, Ghadirian P, Foulkes WD: The role of genetic factors in the etiology of pancreatic adenocarcinoma: an update. Cancer Invest 2001; 19:65-75.
3. Smeenk HG, Tran TC, Erdmann J, et al.: Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg 2005; 390:94-103.
4. Lockhart AC, Rothenberg ML, Berlin JD: Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology, 2005; 128:1642-1654.
5. Wettenhall JM, Smyth GK: limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 2004; 20:3705-3706.
6. Moch H, Schraml P, Bubendorf L, et al.: High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 1999; 54:981-986.
7. Chen JJ, Wu R, Yang PC, et al.: Profiling expression pattern and isolating differentially expressed genes by cDNA microarray system with colorimetry detection. Genomics 1998; 51:313-324.
8. Hartupee JC, Zhang H, Bonaldo MF, et al.: Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: Reg IV. Biochim Biophys Acta 2001; 1518:287-293.
9. Violette S, Festor E, Pandrea-Vasile I, et al.: Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas. Int J Cancer 2003; 103:185-193.
10. Broekaert D, Eyckerman S, Lavens D, et al.: Comparison of leptin- and interleukin-6-regulated expression of the rPAP gene family: evidence for differential co-regulatory signals. Eur Cytokine Netw 2002; 13:78-85.
11. Simon MT, Pauloin A, Normand G, et al.: HIP/PAP stimulates liver regeneration after partial hepatectomy and combines mitogenic and anti-apoptotic functions through the PKA signaling pathway. FASEB J, 2003; 17:1441-1450.
12. Bishnupuri KS, Luo Q, Sainathan SK, et al.: Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis. Gastroenterology 2010; 138:616-626.
13. Rafa L, Dessein AF, Devisme L, et al.: REG4 acts as a mitogenic, motility and pro-invasive factor for colon cancer cells. Int J Oncol 2010; 36:689-698.
14. Mitani Y, Oue N, Matsumura S, et al.: Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene 2007; 26:4383-4393.
15. Bishnupuri KS, Luo Q, Murmu N, et al.: Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology 2006; 130:137-149.
16. Kuniyasu H, Oue N, Sasahira T, et al.: Reg IV enhances peritoneal metastasis in gastric carcinomas. Cell Prolif 2009; 42:110-121.
17. Miyagawa K, Sakakura C, Nakashima S, et al.: Overexpression of RegIV in peritoneal dissemination of gastric cancer and its potential as A novel marker for the detection of peritoneal micrometastasis. Anticancer Res 2008; 28:1169-1179.
18. Li XH, Zheng Y, Zheng HC, et al.: REG IV overexpression in an early stage of colorectal carcinogenesis: an immunohistochemical study. Histol Histopathol 2010; 25:473-484.
19. Yamagishi H, Fukui H, Sekikawa A, et al.: Expression profile of REG family proteins REG Ialpha and REG IV in advanced gastric cancer: comparison with mucin phenotype and prognostic markers. Mod Pathol 2009; 22:906-913.
20. Ohara S, Oue N, Matsubara A, et al.: Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer. Cancer Sci 2008; 99:1570-1577.
21. Hayashi T, Matsubara A, Ohara S, et al.: Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker. Oncol Rep 2009; 21:95-100.
22. Takehara A, Eguchi H, Ohigashi H, et al.: Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci 2006; 97:1191-1197.
23. Heiskala K, Arola J, Heiskala M, et al.: Expression of Reg IV and Hath1 in neuroendocrine neoplasms. Histol Histopathol 2010; 25:63-72.
24. Tamura H, Ohtsuka M, Washiro M, et al.: Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol 2009; 40:1686-1692.
25. Sasahira T, Oue N, Kirita T, et al.: Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland. Histopathology 2008; 53:667-675.
26. Nanakin A, Fukui H, Fujii S, et al.: Expression of the REG IV gene in ulcerative colitis. Lab Invest 2007; 87:304-314.
27. Suyama K, Shapiro I, Guttman M, et al.: A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002; 2:301-314.
28. Hazan RB, Phillips GR, Qiao RF, et al.: Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 2000; 148:779-790.
29. Wheelock MJ, Johnson KR: Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 2003; 19:207-235.
30. Taniuchi K, Nakagawa H, Hosokawa M, et al.: Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rhofamily GTPases. Cancer Res 2005; 65:3092-3099.
31. Kovács A, Schmidt E, Bégány A, et al.: Immunohistochemical examination of P-cadherin in bullous and acantholytic skin diseases. Acta Derm Venereol 2004; 84:116-119.
32. Patel IS, Madan P, Getsios S, et al.: Cadherin switching in ovarian cancer progression. Int J Cancer 2003; 106:172-177.
33. Bauer K, Dowejko A, Bosserhoff AK, et al.: P-cadherin induces an epithelial-like phenotype in oral squamous cell carcinoma by GSK-3beta-mediated Snail phosphorylation. Carcinogenesis 2009; 30:1781-1788.
34. Pyo SVV, Hashimoto M, Kim YS, et al.: Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome. J Craniomaxillofac Surg 2007; 35:1-9.
35. Paredes J, Albergaria A, Oliveira JT, et al.: P-cadherin over-expression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 2005; 11:5869-5877.
36. Stefansson IM, Salvesen HB, Akslen LA: Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004; 22:1242-1252.
37. Nakamura T, Furukawa Y, Nakagawa H, et al.: Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 2004; 23:2385-2400.
38. Obama K, Ura K, Li M, et al.: Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 2005; 41:1339-1348.
39. Hibi K, Kitamura YH, Mizukami H, et al.: Frequent CDH3 demethylation in advanced gastric carcinoma. Anticancer Res 2009; 29:3945-3947.
40. Hibi K, Goto T, Mizukami H, et al.: Demethylation of the CDH3 gene is frequently detected in advanced colorectal cancer. Anticancer Res 2009; 29:2215-2217.
41. Gribenko AV, Hopper JE, Makhatadze GI: Molecular characterization and tissue distribution of a novel member of the S100 family of EF-hand proteins. Biochemistry 2001; 40:15538-15548.
42. Donato R: S100: a multigenic family of calciummodulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001; 33:637-668.
43. Ghavami S, Kerkhoff C, Chazin WJ, et al.: S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HtrA2. Biochim Biophys Acta 2008; 1783:297-311.
44. Svenningsson P, Chergui K, Rachleff I, et al.: Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006; 311:77-80.
45. Tirkos S, Newbigging S, Nguyen V, et al.: Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator. Respir Res 2006; 7:51.
46. Ebihara T, Endo R, Kikuta H, et al.: Differential gene expression of S100 protein family in leukocytes from patients with Kawasaki disease. Eur J Pediatr 2005; 164:427-431.
47. Filipek A, Jastrzebska B, Nowotny M, et al.: CacyBP/SIP, a calcyclin and Siah-1-interacting protein, binds EF-hand proteins of the S100 family. J Biol Chem 2002; 277:28848-28852.
48. Fuentes MK, Nigavekar SS, Arumugam T, et al.: RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 2007; 50:1230-1240.
49. 2+-dependent binding and activation of dormant ezrin by dimeric S100P. Mol Biol Cell 2003; 14:2372-2384.
50. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al.: Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol 2005; 166:81-92.
51. Wang G, Platt-Higgins A, Carroll J, et al.: Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 2006; 66:1199-1207.
52. Birkenkamp-Demtroder K, Olesen SH, Sørensen FB, et al.: Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005; 54:374-384.
53. Hammacher A, Thompson EW, Williams ED: Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int J Biochem Cell Biol 2005; 37:442-450.
54. Ohuchida K, Mizumoto K, Egami T, et al.: S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res 2006; 12:5411-5416.
55. Shyu RY, Huang SL, Jiang SY: Retinoic acid increases expression of the calcium-binding protein S100P in human gastric cancer cells. J Biomed Sci 2003; 10:313-319.
56. Li Y, St John MA, Zhou X, et al.: Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004; 10:8442-8450.
57. Bartling B, Rehbein G, Simm A, et al.: Porcupine expression is associated with the expression of S100P and other cancer-related molecules in non-small cell lung carcinoma. Int J Oncol 2010; 36:1015-1021.
58. Yoo HJ, Yun BR, Kwon JH, et al.: Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells. Exp Mol Med 2009; 41:102-115.
59. Yao R, Lopez-Beltran A, Maclennan GT, et al.: Expression of S100 protein family members in the pathogenesis of bladder tumors. Anticancer Res 2007; 27:3051-3058.
60. Zhi H, Zhang J, Hu G, et al.: The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer 2003; 106:327-333.
61. Schor AP, Carvalho FM, Kemp C, et al.: S100P calcium-binding protein expression is associated with high-risk proliferative lesions of the breast. Oncol Rep 2006; 15:3-6.
62. Bartling B, Rehbein G, Schmitt WD, et al.: S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 2007; 43:1935-1943.